Search Results - "Ricigliano, Mark"
-
1
ADR-201: A novel cytotoxic drug-conjugate for pancreatic cancer
Published in Journal of clinical oncology (20-05-2017)“…Abstract only e14018 Background:Standard of care treatment for pancreatic adenocarcinoma (PDAC) consists of FOLFIRINOX or gemcitabine with nab-paclitaxel used…”
Get full text
Journal Article -
2
Use of phenotypic profiling to determine sensitivity of gemcitabine with nab-paclitaxel for front-line treatment of pancreatic cancer
Published in Journal of clinical oncology (20-05-2017)“…Abstract only e15749 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) consists of FOLFIRINOX (FFX) or gemcitabine with…”
Get full text
Journal Article -
3
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer
Published in Clinical cancer research (15-10-2014)“…Despite a challenging prognosis, modern cytotoxic therapy can induce tumor responses and extend life in pancreatic adenocarcinoma (PDAC). Pharmacogenomic (PGx)…”
Get full text
Journal Article -
4
Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity
Published in Journal of clinical oncology (20-05-2016)“…Abstract only…”
Get full text
Journal Article -
5
Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer
Published in Journal of clinical oncology (01-02-2017)“…Abstract only 338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in…”
Get full text
Journal Article -
6
Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic adenocarcinoma (PDAC)
Published in Journal of clinical oncology (20-05-2016)“…Abstract only…”
Get full text
Journal Article -
7
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma
Published in Cancers (24-11-2018)“…Previous studies have shown that pharmacogenomic modeling of circulating tumor and invasive cells (CTICs) can predict response of pancreatic ductal…”
Get full text
Journal Article -
8
Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting
Published in Journal of clinical oncology (20-05-2014)“…Abstract only…”
Get full text
Journal Article -
9
Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors
Published in Journal of clinical oncology (20-05-2012)“…Abstract only 3066 Background: Circulating tumorigenic cells (CTCs) may be responsible for tumor progression, represent a new source of information of tumor…”
Get full text
Journal Article -
10
Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance
Published in Journal of clinical oncology (20-05-2013)“…Abstract only 4017 Background: Pancreatic adenocarcinoma (PDAC) is uniformly lethal and is the 4th leading cause of cancer mortality. Despite this, modern…”
Get full text
Journal Article -
11
Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance
Published in Journal of clinical oncology (01-02-2013)“…Abstract only 142 Background: Pancreatic adenocarcinoma (PDAC) is uniformly lethal; despite this, modern cytotoxics (C) can induce tumor responses and extend…”
Get full text
Journal Article